We are developing a new generation of biotechnology drugs that act precisely within a targeted diseased tissue

About Valitor

Valitor, Inc. has developed novel methods of modifying therapeutic proteins to achieve substantial control over their pharmacokinetics, target specificity and bioactivity.

Our technology platform can be broadly applied to improve the pharmacological properties of many protein drugs that are currently approved or under development

Our lead product will be used to improve the treatment of diseases in ophthalmology. We also have development pipelines for products in the fields of oncology and orthopedics.

About Valitor

Valitor, Inc. has developed novel methods of modifying therapeutic proteins to achieve substantial control over their pharmacokinetics, target specificity and bioactivity.

Our technology platform can be broadly applied to improve the pharmacological properties of many protein drugs that are currently approved or under development.

Our lead product will be used to improve the treatment of diseases in ophthalmology. We also have development pipelines for products in the fields of oncology and orthopedics.

Our Technology

We have developed methods to tether bioactive molecules (e.g., growth factors, antibodies, receptor ligands, etc.) to single-chain, soluble biopolymers such as hyaluronic acid.

+

=

Therapeutic proteins

Biopolymer

Protein conjugates

By coupling one or more bioactive molecules to the polymers at defined ratios, we can formulate drugs with the following advantages over unmodified drug products:

1. Enhanced efficacy after local administration

2. Less frequent administration (more convenient and improved safety)

3. Enable the use of best-in-class drugs for new clinical indications

Using this technology, we have initiated the development of three protein-based therapies that we expect will dramatically improve the current treatment strategies for a variety of diseases.